2021 TDDW
Symposium (XIV) HBV/HCC SYMPOSIUMS
RISK OF OCCURRENCE AND RECURRENCE OF HCC UNDER NUCS TREATMENT I-Cheng Lee Division of Gastroenterology and Hepatology, Taipei Veterans General Hospital, Taipei, Taiwan HBV infection is the leading cause of hepatocellular carcinoma (HCC) worldwide, and patients with HBV infection are exposed to the risk of HCC occurrence throughout their life. Patients with high HBV viral load or cirrhosis are at highest risk of HCC development, and antiviral therapy has been shown to decrease the risk of HCC occurrence and recurrence. However, HCC may still occur in patients without cirrhosis, in patients
with low viral loads, in patients under antiviral therapy, and even in patients achieving HBsAg seroclearance. In this topic we will summarize the current knowledge of the mechanisms of HCC occurrence and recurrence under NUCs treatment, the predictors and risk scores of HCC occurrence and recurrence, and strategies to minimize the risk of HCC.
81
